- Home
- CRML vs XERS Comparison
CRML vs XERS Comparison
Compare CRML & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- XERS
- Stock Information
- Founded
- CRML N/A
- XERS 2005
- Country
- CRML United States
- XERS United States
- Employees
- CRML N/A
- XERS N/A
- Industry
- CRML
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- XERS Health Care
- Exchange
- CRML NYSE
- XERS Nasdaq
- Market Cap
- CRML 634.1M
- XERS 509.9M
- IPO Year
- CRML N/A
- XERS 2018
- Fundamental
- Price
- CRML $6.74
- XERS $3.40
- Analyst Decision
- CRML
- XERS Buy
- Analyst Count
- CRML 0
- XERS 3
- Target Price
- CRML N/A
- XERS $4.87
- AVG Volume (30 Days)
- CRML 20.7K
- XERS 1.6M
- Earning Date
- CRML 02-01-2025
- XERS 11-08-2024
- Dividend Yield
- CRML N/A
- XERS N/A
- EPS Growth
- CRML N/A
- XERS N/A
- EPS
- CRML N/A
- XERS N/A
- Revenue
- CRML $117,660.00
- XERS $187,361,000.00
- Revenue This Year
- CRML N/A
- XERS $23.48
- Revenue Next Year
- CRML N/A
- XERS $18.69
- P/E Ratio
- CRML N/A
- XERS N/A
- Revenue Growth
- CRML 5.79
- XERS 22.72
- 52 Week Low
- CRML $5.32
- XERS $1.69
- 52 Week High
- CRML $22.50
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- CRML 47.79
- XERS 50.76
- Support Level
- CRML $6.25
- XERS $3.26
- Resistance Level
- CRML $6.86
- XERS $3.63
- Average True Range (ATR)
- CRML 0.75
- XERS 0.17
- MACD
- CRML -0.08
- XERS -0.02
- Stochastic Oscillator
- CRML 19.68
- XERS 15.57
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.